References
- Tighe MP, Afzal NA, Bevan A, et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs 2009;11:185-202
- Colletti RB, Di Lorenzo C. Overview of pediatric gastroesophageal reflux disease and proton pump inhibitor therapy. J Pediatr Gastroenterol Nutr 2003;37(Suppl 1):S7-S11.
- Vandenplas Y. Management of paediatric GERD. Nat Rev Gastroenterol Hepatol 2014;11:147-57
- Vakil N. Disease definition, clinical manifestations, epidemiology and natural history of GERD. Best Pract Res Clin Gastroenterol 2010;24:759-64
- Ruigómez A, Wallander MA, Lundborg P, et al. Gastroesophageal reflux disease in children and adolescents in primary care. Scand J Gastroenterol 2010;45:139-46
- Croxtall JD, Perry CM, Keating GM. Esomeprazole in gastroesophageal reflux disease in children and adolescents. Pediatr Drugs 2008;10:199-205
- Cezard JP. Managing gastro-oesophageal reflux disease in children. Digestion 2004;69(Suppl 1):3-8
- Lightdale JR, Gremse DA, Section on gastroenterology hepatology and nutrition. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics 2013;131:e1684-95
- NICE Guidelines. Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people. 2015 [updated January, 2015]. http://www.nice.org.uk/guidance/ng1. [Last accessed 5 June 2015]
- Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7
- Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401
- Stuart-Buttle CD, Read JD, Sanderson HF, et al. A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996:75-9
- O’Neil M, Payne C, Read J. Read codes Version 3: a user led terminology. Methods Inf Med 1995;34:187-92
- First Databank. MULTILEX for primary care. 2010. http://www.fdbhealth.co.uk/multilex-overview/. [Last accessed 4 December 2012]
- Herings RMC, Pedersen L. Pharmacy-based medical record linkage systems. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. Chichester, UK: Wiley-Blackwell; 2012. p 270-86
- van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010;46:395-404
- Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007;150:262-7
- van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics 2011;127:925-35
- Johnson DA, Oldfield EC, 4th. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol 2013;11:458-64
- Tjon JA, Pe M, Soscia J, et al. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy 2013;33:956-71
- Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008;53:385-93
- Vandenplas Y, Hassall E. Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002;35:119-36